Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00334776 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 6 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT00669019 | Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00281957 | Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT02142335 | Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma | unknown | Phase 2 | 17 | California Cancer Assocaties for Research & ExcellenceOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00436605 | Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01166126 | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00651157 | Viral Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 22, 2014 | clinicaltrials |
| NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Ludwig Institute for Cancer ResearchOTHER | 0 | Apr 1, 2014 | clinicaltrials |
| NCT01014351 | Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | completed | Phase 2 | 70 | SCRI Development Innovations, LLCOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00004135 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer | completed | Phase 2 | 19 | University of ChicagoOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00084214 | STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma | completed | Phase 1 / Phase 2 | 103 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Mar 6, 2014 | clinicaltrials |
| NCT00631618 | Clinical Trial of Sutent to Treat Metastatic Melanoma | completed | Phase 2 | 12 | California Pacific Medical Center Research InstituteOTHER | 1 | Feb 25, 2014 | clinicaltrials |
| NCT01055522 | Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma | terminated | Phase 2 | 102 | Philogen S.p.A.INDUSTRY | 4 | Feb 25, 2014 | clinicaltrials |
| NCT01933061 | Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma | withdrawn | Phase 2 | 0 | Celgene CorporationINDUSTRY | 0 | Feb 4, 2014 | clinicaltrials |
| NCT00012064 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma | completed | Phase 1 / Phase 2 | 56 | Lisata Therapeutics, Inc.INDUSTRY | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00553683 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | unknown | Phase 1 / Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00002817 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00436930 | Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma | completed | Phase 2 | 200 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00489944 | Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma | unknown | Phase 2 | 50 | San Diego Pacific Oncology & Hematology AssociatesOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00492505 | Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma | unknown | Phase 2 | 200 | San Diego Pacific Oncology & Hematology AssociatesOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00538005 | Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma | unknown | Phase 1 / Phase 2 | 54 | San Diego Pacific Oncology & Hematology AssociatesOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00462423 | Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study(AbraxAvast) | completed | Phase 2 | 50 | Lynn E. Spitler, MDOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00004025 | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00010309 | Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00002845 | Interleukin-2 in Treating Patients With Metastatic Melanoma | unknown | Phase 2 | 20 | Blumenthal Cancer Center at Carolinas Medical CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00081042 | ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma | completed | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00128583 | Vaccine Therapy in Treating Patients With Malignant Melanoma | unknown | Phase 2 | — | CancerVax CorporationINDUSTRY | 2 | Dec 19, 2013 | clinicaltrials |
| NCT00402662 | A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | terminated | Phase 2 | 3 | Yale UniversityOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00597038 | A Phase I/II Study of Dasatinib and Dacarbazine | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00598507 | Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma | completed | Phase 2 | 35 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT00278122 | Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | suspended | Phase 2 | 42 | University of VirginiaOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT00005875 | Nitrocamptothecin in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00358319 | Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma | terminated | Phase 1 / Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00007969 | Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | — | QLT Inc.INDUSTRY | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00107159 | Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma | completed | Phase 2 | 37 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00255762 | Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2013 | clinicaltrials |
| NCT00526149 | BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors | completed | Phase 2 | 76 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Oct 7, 2013 | clinicaltrials |
| NCT01944709 | Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma | terminated | Phase 1 / Phase 2 | 2 | Prof. Dr. Silke GillessenOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00126685 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 30 | Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum ErlangenOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00147550 | MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. | terminated | Phase 1 / Phase 2 | 79 | PfizerINDUSTRY | 1 | Sep 13, 2013 | clinicaltrials |
| NCT00498836 | Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 18 | Clavis PharmaINDUSTRY | 3 | Sep 12, 2013 | clinicaltrials |
| NCT00002952 | Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 20 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00004141 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 46 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00203879 | Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma | completed | Phase 2 | 19 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT01743157 | Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma(BBI) | completed | Phase 1 / Phase 2 | 24 | California Pacific Medical Center Research InstituteOTHER | 1 | Aug 29, 2013 | clinicaltrials |
| NCT01082198 | Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes | unknown | Phase 1 / Phase 2 | 22 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01217398 | Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye | unknown | Phase 2 | 35 | Institut CurieOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00246012 | A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma | completed | Phase 1 / Phase 2 | 144 | Centocor, Inc.INDUSTRY | 3 | Aug 19, 2013 | clinicaltrials |
| NCT00563823 | Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery | completed | Phase 2 | 34 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Aug 2, 2013 | clinicaltrials |
Data updated 23 days agoSource updated May 21, 2014source: clinicaltrials